Ireland - English - HPRA (Health Products Regulatory Authority)

novartis animal health ireland ltd - nitroscanate - tablets - 500 milligram - canine - endoparasiticide

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis agribusiness ire. ltd - nitroscanate - tablets - canine - endoparasiticide

Canada - English - Health Canada

elanco canada limited - nitroscanate - tablet - 100mg - nitroscanate 100mg - dogs

Canada - English - Health Canada

elanco canada limited - nitroscanate - tablet - 500mg - nitroscanate 500mg - dogs

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

novartis animal health australasia pty. limited - nitroscanate - parasiticides - dog | bitch | castrate | puppy - internal parasite | haemonchus spp. | ostertagia spp. | stomach flukes | tapeworm

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

novartis animal health australasia pty. limited - nitroscanate - parasiticides - dog | bitch | castrate | puppy - internal parasite | haemonchus spp. | ostertagia spp. | stomach flukes | tapeworm

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - baricitinib, quantity: 2 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; mannitol; microcrystalline cellulose; polyvinyl alcohol; titanium dioxide; macrogol 3350; purified talc; lecithin; iron oxide red - rheumatoid arthritis,olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately, or who are intolerant, to one or more dmards.,olumiant can be taken as monotherapy or in combination with cdmards, including methotrexate (mtx).,atopic dermatitis,olumiant is indicated for the treatment of moderate to severe atopic dermatitis (ad) in adult patients who are candidates for systemic therapy.,alopecia areata,olumiant is indicated for the treatment of severe alopecia areata (aa) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 pharmacodynamic properties; clinical trials).

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - bosentan - film-coated tablet - bosentan 62.5 mg - antihypertensives

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - bosentan - film-coated tablet - bosentan 125 mg - antihypertensives